Physician profile
Travis Forney
NPI 1285039297
$665.14
in general payments reported to CMS, 2019-2025
15 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $107.97 | 2025 | Rybrevant, Tecvayli, Darzalex |
| Jazz Pharmaceuticals INC. | $80.28 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $79.66 | 2025 | Lynparza, Calquence |
| Genentech USA, INC. | $79.30 | 2025 | Polivy, Itovebi, Gazyva |
| Abbvie INC. | $70.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.79 | 2025 | Hyqvia, Vonvendi |
| Tersera Therapeutics LLC | $27.83 | 2025 | Zoladex |
| Incyte Corporation | $26.41 | 2025 | Zynyz, Monjuvi |
| Csl Behring | $22.79 | 2025 | Privigen |
| Melinta Therapeutics, LLC | $21.22 | 2025 | Rezzayo |
| Eisai INC. | $20.66 | 2025 | |
| Adc Therapeutics America, INC. | $20.43 | 2025 | |
| Merck Sharp & Dohme LLC | $16.48 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Pharmaand Gmbh | $15.16 | 2025 | Rubraca |
| Tolmar, INC. | $15.16 | 2025 | Rubraca, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Forney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.